Brief: Uniqure Announces Preliminary Data On First Cohort In Phase I/IIA Clinical Trial Of AMT-260
19/06/2026 15:39
BRIEF-Uniqure Announces Preliminary Data On First Cohort In Phase I/IIA Clinical Trial Of AMT-260 June 19 (Reuters) - Uniqure NV UQ1.F:
UNIQURE ANNOUNCES PRELIMINARY DATA ON THE FIRST COHORT IN THE PHASE I/IIA CLINICAL TRIAL OF AMT-260 IN REFRACTORY MESIAL TEMPORAL LOBE EPILEPSY
UNIQURE NV - NO SERIOUS ADVERSE EVENTS REPORTED IN LOW-DOSE COHORT; ALL EVENTS MILD OR MODERATE
Source text: ID:nGNX8rqzZq
Further company coverage: UQ1.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal